Drug
APIM-containing Peptide ATX-101 clinical trials
Also written ATX-101.
- studies test it
- 16
- open now
- 0
- in phase 3
- 2
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
- ATX-101
- 11
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 5
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 2
Kythera Biopharmaceuticals (10) · Allay Therapeutics, Inc. (2) · Aurobac Therapeutics SAS (1) · Northwestern University (1) · THERAPIM PTY LTD (1) · Benjamin Izar (1)
Often tested with
Tested in the same studies.
Moxifloxacin (1) · Carboplatin (1) · Liposomal doxorubicin (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses APIM-containing Peptide ATX-101 is read from its arms, and is right about nine times in ten.
Testing it · 16
- Phase 2B Study Assessing Pain Relief After Replacement of the KneeCompletedPhase 2Allay Therapeutics, Inc.NCT06799845Written as ATX101
- Phase 1 Single Ascending Dose Study With ATX101CompletedPhase 1Aurobac Therapeutics SASNCT07107802Written as ATX101
- Study Assessing Pain Relief After Replacement of the KneeTerminatedPhase 2Allay Therapeutics, Inc.NCT05260008Written as ATX-101
- Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back FatTerminatedNot applicableNorthwestern UniversityNCT03284034Written as ATX-101
- A Study to Evaluate the Combination of ATX-101 and Platinum-based ChemotherapyTerminatedPhase 1/2THERAPIM PTY LTDNCT04814875Written as ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
- ATX-101 in Advanced Dedifferentiated Liposarcoma and LeiomyosarcomaTerminatedPhase 2Benjamin IzarNCT05116683Written as ATX-101
- Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101CompletedPhase 2Kythera BiopharmaceuticalsNCT02159729Written as ATX-101 (1 mg/cm^2)
- Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of AgeCompletedPhase 3Kythera BiopharmaceuticalsNCT02123134Written as ATX-101
- Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101CompletedPhase 3Kythera BiopharmaceuticalsNCT02163902Written as ATX-101
- To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT01462786Written as ATX-101
- Dose-Escalation Safety and Pharmacokinetic Study of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT00618709Written as ATX-101
- Evaluation of the Effect of ATX-101 on QT/QTc IntervalsCompletedPhase 1Kythera BiopharmaceuticalsNCT01706679Written as ATX-101 (10 mg/ml)
- Open-Label Pharmacokinetic Study of Final Formulations of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT01632917Written as ATX-101 - U.S.
- Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat TissueCompletedPhase 1Kythera BiopharmaceuticalsNCT01319916Written as ATX-101
- A Study to Assess Injection Comfort of Two Formulations of ATX-101CompletedPhase 1Kythera BiopharmaceuticalsNCT01320761Written as ATX-101-BA-free
- ATX-101 AbdominoplastyCompletedPhase 1Kythera BiopharmaceuticalsNCT00835952Written as ATX-101